Sugi Predict

Sugi Predict / Compounds / SCHEMBL3975486

SCHEMBL3975486

SCHEMBL3975486

COc1cc(O)nc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.63
▸ LMNA P02545 2/20 0.62
▸ HPGD P15428 2/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ ALDH1A1 P00352 3/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ MAPT P10636 2/20 0.55
▸ HTT P42858 1/20 0.55
▸ SLC2A1 P11166 1/20 0.54
▸ POLB P06746 5/20 0.50
▸ NQO2 P16083 2/20 0.50
▸ TLR8 Q9NR97 1/20 0.47
▸ RAD52 P43351 1/20 0.46
▸ CYP1A1 P04798 2/20 0.46
▸ CYP1B1 Q16678 2/20 0.46
▸ GUSB P08236 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ ACACA Q13085 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28606045 0.98 ALOX15 (0.61) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL3975484 0.81 ALOX15 (0.42) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL30065410 0.79 HPGD (0.64) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL396614 0.79 HPGD (0.64) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL266444 0.79 LMNA (0.64) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL29877118 0.79 LMNA (0.64) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL28010962 0.79 LMNA (0.64) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL6229640 0.79 ALOX15 (0.47) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL19689623 0.79 ESR1 (0.49) ALOX15LMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL2641459 0.78 SMN1; SMN2 (0.62) ALOX15LMNAHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113201028-B Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2022-12-09 — — CN claimed
CN-113201028-A Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2021-08-03 — — CN claimed
CN-113201028-B Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2022-12-09 — — CN disclosed
CN-113201028-A Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2021-08-03 — — CN disclosed
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 — — US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 — — US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 — — US disclosed
EP-1351688-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2006-01-04 — — EP disclosed
US-6936620-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL MYERS SQUIBB COMPANY (US) 2005-08-30 — — US disclosed
US-6818655-B2 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2004-11-16 — — US disclosed
EP-1359915-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM (US) 2004-07-21 — — EP disclosed
EP-1351687-A2 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-15 — — EP disclosed
WO-2003053940-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-$G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 — — WO disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 — — WO disclosed
WO-2002058702-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (GB) 2002-08-01 — — WO disclosed
WO-2002047687-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-20 — — WO disclosed
WO-2002047456-A2 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-20 — — WO disclosed
EP-0317188-B1 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1995-09-27 — — EP disclosed
US-5114940-A Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides ROUSSEL-UCLAF (FR) 1992-05-19 — — US disclosed
EP-0317188-A2 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1989-05-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 ALOX15 1789/4885LMNA 435/4885HPGD 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.